These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34329709)

  • 1. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art.
    Veloso PM; Machado R; Nobre C
    Eur J Pharm Biopharm; 2021 Oct; 167():89-103. PubMed ID: 34329709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [DDS preparations of drugs for inflammatory bowel disease].
    Takada K
    Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Rasmussen SN
    J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
    Wiersma H; Escher JC; Dilger K; Trenk D; Benninga MA; van Boxtel CJ; Taminiau J
    Inflamm Bowel Dis; 2004 Sep; 10(5):626-31. PubMed ID: 15472525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.
    Brzezinski A; Rankin GB; Seidner DL; Lashner BA
    Cleve Clin J Med; 1995; 62(5):317-23. PubMed ID: 7586488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: the use of mesalazine in inflammatory bowel disease.
    Bergman R; Parkes M
    Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    Christensen LA; Jacobsen BA
    Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
    Bautzová T; Rabišková M; Lamprecht A
    Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mulder CJ; van den Hazel SJ
    Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
    Kao J; Kwok K; Das KM
    J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: Oral, modified-release mesalazine formulations--proprietary versus generic.
    Forbes A; Cartwright A; Marchant S; McIntyre P; Newton M
    Aliment Pharmacol Ther; 2003 May; 17(10):1207-14. PubMed ID: 12755834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
    Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
    Klotz U
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():16-22. PubMed ID: 10194943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of Mesalamine levels in Human Milk as a Function of Dose.
    Datta P; Rewers-Felkins K; Kallem RR; Baker T; Hale TW
    Breastfeed Med; 2019 Mar; 14(2):98-101. PubMed ID: 30431332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical effects of 5-aminosalicylic acid preparations in Crohn disease].
    Fleig WE
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():22-5. PubMed ID: 10194944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.